The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Pharmacotherapy of Traumatic Brain Injury: State of the Science and the Road Forward: Report of the Department of Defense Neurotrauma Pharmacology Workgroup
Open accessAbstract
Despite substantial investments by government, philanthropic, and commercial sources over the past several decades, traumatic brain injury (TBI) remains an unmet medical need and a major source of disability and mortality in both developed and developing societies. The U.S. Department of Defense neurotrauma research portfolio contains more than 500 research projects funded at more than $700 million and is aimed at developing interventions that mitigate the effects of trauma to the nervous system and lead to improved quality of life outcomes. A key area of this portfolio focuses on the need for effective pharmacological approaches for treating patients with TBI and its associated symptoms. The Neurotrauma Pharmacology Workgroup was established by the U.S. Army Medical Research and Materiel Command (USAMRMC) with the overarching goal of providing a strategic research plan for developing pharmacological treatments that improve clinical outcomes after TBI. To inform this plan, the Workgroup (a) assessed the current state of the science and ongoing research and (b) identified research gaps to inform future development of research priorities for the neurotrauma research portfolio. The Workgroup identified the six most critical research priority areas in the field of pharmacological treatment for persons with TBI. The priority areas represent parallel efforts needed to advance clinical care; each requires independent effort and sufficient investment. These priority areas will help the USAMRMC and other funding agencies strategically guide their research portfolios to ensure the development of effective pharmacological approaches for treating patients with TBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased mortality associated with growth hormone treatment in critically ill adults
Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., & Hinds, C. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411102 · Cited by 1,023
N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency
Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Progesterone synthesis and myelin formation by Schwann cells
Koenig, H. L., Schumacher, M., Ferzaz, B., Thi, A. N. D., Ressouches, A., Guennoun, R., Jung-Testas, I., Robel, P., Akwa, Y., & Baulieu, E.-E. (1995) · Science · doi:10.1126/science.7770777 · Cited by 480
Kelly, D. F., Gaw Gonzalo, I. T., Cohan, P., Berman, N., Swerdloff, R., & Wang, C. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.93.5.0743 · Cited by 455
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Hypopituitarism Secondary to Head Trauma
Benvenga, S. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1353 · Cited by 423
N -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
Mechanism of action of methylphenidate: Insights from PET imaging studies
Volkow, N. D., Fowler, J. S., Wang, G., Ding, Y., & Gatley, S. J. (2002) · Journal of Attention Disorders · doi:10.1177/070674370200601s05 · Cited by 353
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321
Prevalence of Neuroendocrine Dysfunction in Patients Recovering from Traumatic Brain Injury
Lieberman, S. A. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2752 · Cited by 261
Hoffer, M. E., Balaban, C., Slade, M. D., Tsao, J. W., & Hoffer, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054163 · Cited by 207
Saatman, K. E., Contreras, P. C., Smith, D. H., Raghupathi, R., McDermott, K. L., Fernandez, S. C., Sanderson, K. L., Voddi, M., & McIntosh, T. K. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6629 · Cited by 185
Effect of growth hormone replacement therapy on cognition after traumatic brain injury
High, W. M., Briones-Galang, M., Clark, J. A., Gilkison, C., Mossberg, K. A., Zgaljardic, D. J., Masel, B. E., & Urban, R. J. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2009.1253 · Cited by 176 · cited 1×
“In the High Study, the dose of rhGH was titrated until a normal IGF-1 plasma level was achieved.(142) In the other two studies, GH was administered at a constant dose, 1 mg/day.”
Wilkinson, C. W., Pagulayan, K. F., Petrie, E. C., Mayer, C. L., Colasurdo, E. A., Shofer, J. B., Hart, K. L., Hoff, D., Tarabochia, M. A., & Peskind, E. R. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00011 · Cited by 162
Robertson, C. L., Puskar, A., Hoffman, G. E., Murphy, A. Z., Saraswati, M., & Fiskum, G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.09.014 · Cited by 152
Reimunde, P., Quintana, A., Castañón, B., Casteleiro, N., Vilarnovo, Z., Otero, A., Devesa, A., Otero-Cepeda, X. L., & Devesa, J. (2011) · Brain Injury · doi:10.3109/02699052.2010.536196 · Cited by 100
Growth hormone (GH) and brain trauma
Devesa, J., Reimunde, P., Devesa, P., Barberá, M., & Arce, V. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.02.022 · Cited by 87
Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial
Sacktor, N., Miyahara, S., Deng, L., Evans, S., Schifitto, G., Cohen, B. A., Paul, R., Robertson, K., Jarocki, B., Scarsi, K., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0412 · Cited by 87
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86
Campbell, J. N., Register, D., & Churn, S. B. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2011.1761 · Cited by 70
Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia ischemia
Wang, L. S., Zhou, J., Shao, X. M., & Tang, X. C. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02977-3 · Cited by 65 · cited 1×
“provided some attenuation of cognitive deficits in neonatal rats after hypoxia-ischemia.(46) Huperzine A also improved memory in rats with scopolamine-induced deficits.”
Cited by
Mondello, S., Kobeissy, F., Vestri, A., Hayes, R. L., Kochanek, P. M., & Berger, R. P. (2016) · Scientific Reports · doi:10.1038/srep28203 · Cited by 110
Self-citationHaber, M., Abdel Baki, S. G., Grin'kina, N. M., Irizarry, R., Ershova, A., Orsi, S., Grill, R. J., Dash, P., & Bergold, P. J. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.09.002 · Cited by 95
Self-citationSigma-1 receptor: a potential therapeutic target for traumatic brain injury
Shi, M., Chen, F., Chen, Z., Yang, W., Yue, S., Zhang, J., & Chen, X. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.685201 · Cited by 58
Lipponen, A., El-Osta, A., Kaspi, A., Ziemann, M., Khurana, I., KN, H., Navarro-Ferrandis, V., Puhakka, N., Paananen, J., & Pitkänen, A. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0519-z · Cited by 47
Metadata
- Authors
- Diaz-Arrastia, R., Kochanek, P. M., Bergold, P., Kenney, K., Marx, C. E., Grimes, C. J. B., Loh, L. Y., Adam, L. G. E., Oskvig, D., Curley, K. C., & Salzer, C. W.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2014-01
- Volume
- 31
- Issue
- 2
- Pages
- 135-158
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2316762748
- Cited by
- 262
- References
- 22
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
